Please login to the form below

Not currently logged in
Email:
Password:

Epidiolex

This page shows the latest Epidiolex news and features for those working in and with pharma, biotech and healthcare.

Medicinal cannabis firm Althea enters UK market

Medicinal cannabis firm Althea enters UK market

For now, it says the default choice for treatment is GW Pharma’s Epidiolex, which is approved in the US but not in Europe, and is says it does not recommend

Latest news

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    in the body where the tumour originated (after Merck &Co’s Keytruda), and GW Pharma’s epilepsy therapy Epidiolex (cannabidiol) which is the first FDA-approved drug based on cannabis.

  • Medical cannabis now available on prescription, for some Medical cannabis now available on prescription, for some

    Meanwhile, GW Pharma – which has been cultivating medicinal cannabis in the UK for more than 20 years – just recently got approval and favourable scheduling for its cannabis-based epilepsy therapy Epidiolex

  • US approval for first ever cannabis-based medicine US approval for first ever cannabis-based medicine

    Once this recategorisation is completed within the next 90 days, GW Pharma will launch Epidiolex in the US. ... Phase 3 studies showed Epidiolex added to other epilepsy therapies significantly reduced the frequency of seizures in patients with LGS and

  • The year of the blockbuster The year of the blockbuster

    Epidiolex from GW Pharmaceuticals:With a PDUFA date in June, GW Pharmaceuticals’ Epidiolex (plant-derived cannabidiol) has the potential to become the first cannabinoid-based anti-epileptic medication. ... The industry will watch carefully whether

  • GW ascendant as epilepsy drug clears phase III trial GW ascendant as epilepsy drug clears phase III trial

    The 120-patient study revealed that patients given Epidiolex saw a 39% median reduction in monthly seizures after 14 weeks' treatment, compared to a 13% cut in the placebo group. ... GW has been scaling up its commercial organisation and production

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    3. Epidiolex – leading the flowering therapeutic cannabinoid market. The last 12 months have seen a huge growth in interest in the therapeutic potential of cannabis, with authorities now allowing regulated access ... GW Pharma gained an historic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...

Infographics